우울증 치료제 시장 규모 조사 : 약물 유형별, 장애 유형별, 약물 유형별, 지역별 예측(2022-2032년)

The Global Depression Drugs Market was valued at approximately USD 17.95 billion in 2023 and is anticipated to witness impressive growth at a compound annual growth rate (CAGR) of 2.80% through the forecast period of 2024-2032, reaching around USD 22.9 billion by 2032. Depression, clinically known as major depressive disorder (MDD), represents a significant and serious mental health condition characterized by prolonged periods of sadness, hopelessness, and a noticeable lack of interest or pleasure in daily activities. This condition can profoundly affect various aspects of an individual's life, including emotional, cognitive, and physical well-being, often leading to social withdrawal, decreased productivity, and severe cases can even result in suicidal thoughts.

The market for depression drugs is being driven by substantial advancements in drug development, particularly the research and creation of medications with unique mechanisms of action. For instance, ketamine and esketamine, N-methyl-D-aspartate (NMDA) receptor antagonists, have shown promise in treating severe and treatment-resistant depression due to their rapid action compared to traditional antidepressants. Additionally, advancements in pharmacogenomics have facilitated more personalized treatment plans, optimizing drug selection and dosage based on genetic testing, thereby improving efficacy and reducing adverse effects. Also, economic and work-related stress also significantly contributes to the increased demand for depression drugs. Economic challenges such as job loss, financial instability, and mounting debt can lead to heightened stress and anxiety, which are known risk factors for depression. Similarly, workplace stress from heavy workloads, job insecurity, and long hours can result in burnout and exacerbate depressive symptoms. Consequently, the need for effective treatment options, including medication, is rising as these stressors become more prevalent.

Moreover, increasing mental health awareness is playing a crucial role in driving the demand for depression drugs. Public health campaigns and initiatives aimed at reducing the stigma associated with mental health conditions have led to greater recognition and understanding of depression. This has encouraged more individuals to seek help and has resulted in higher diagnosis rates and subsequent prescriptions for depression medications. Enhanced mental health awareness has also led to better-equipped healthcare providers who can identify and treat depression more effectively.

Regionally, North America dominates the global depression drugs market due to a substantial patient population, a well-developed healthcare infrastructure, and significant pharmaceutical research and development activities. High health insurance coverage rates further facilitate access to mental health services and medications. Meanwhile, increased awareness and reduced stigma around mental health issues in North America have driven more individuals to seek treatment, thereby bolstering market growth. Whereas, the market in Asia Pacific is anticipated to grow at the fastest rate over the forecast period 2024-2032

Major market players included in this report are:

• Otsuka Holdings Co., Ltd.
• Pfizer, Inc.
• Eli Lilly and Company
• AstraZeneca plc.
• Novartis AG
• Bristol-Myers Squibb Company
• GlaxoSmithKline plc.
• Takeda Pharmaceutical Co., Ltd.
• AbbVie, Inc.
• Johnson & Johnson

The detailed segments and sub-segment of the market are explained below:

By Drug Class:

• Atypical Antipsychotics
• Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)
• Selective Serotonin Reuptake Inhibitors (SSRIs)
• Central Nervous System (CNS) Stimulants
• Tricyclic Antidepressants
• Monoamine Oxidase Inhibitors
• Others

By Disorder Type:

• Major Depressive Disorder
• Obsessive-Compulsive Disorder
• Generalized Anxiety Disorder
• Panic Disorder
• Others

By Drug Type:

• Generic Drugs
• Branded Drugs

By Region:

• North America
• U.S.
• Canada
• Europe
• UK
• Germany
• France
• Spain
• Italy
• ROE
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• RoAPAC
• Latin America
• Brazil
• Mexico
• RoLA
• Middle East & Africa
• Saudi Arabia
• South Africa
• RoMEA

Years considered for the study are as follows:

• Historical year - 2022
• Base year - 2023
• Forecast period - 2024 to 2032

Key Takeaways:

• Market Estimates & Forecast for 10 years from 2022 to 2032.
• Annualized revenues and regional level analysis for each market segment.
• Detailed analysis of geographical landscape with Country level analysis of major regions.
• Competitive landscape with information on major players in the market.
• Analysis of key business strategies and recommendations on future market approach.
• Analysis of competitive structure of the market.
• Demand side and supply side analysis of the market.

Table of Contents

Chapter 1. Global Depression Drugs Market Executive Summary

• 1.1. Global Depression Drugs Market Size & Forecast (2022-2032)
• 1.2. Regional Summary
• 1.3. Segmental Summary
  • 1.3.1. By Drug Class
  • 1.3.2. By Disorder Type
  • 1.3.3. By Drug Type
• 1.4. Key Trends
• 1.5. Recession Impact
• 1.6. Analyst Recommendation & Conclusion

Chapter 2. Global Depression Drugs Market Definition and Research Assumptions

• 2.1. Research Objective
• 2.2. Market Definition
• 2.3. Research Assumptions
  • 2.3.1. Inclusion & Exclusion
  • 2.3.2. Limitations
  • 2.3.3. Supply Side Analysis
    • 2.3.3.1. Availability
    • 2.3.3.2. Infrastructure
    • 2.3.3.3. Regulatory Environment
    • 2.3.3.4. Market Competition
    • 2.3.3.5. Economic Viability (Consumer's Perspective)
  • 2.3.4. Demand Side Analysis
    • 2.3.4.1. Regulatory frameworks
    • 2.3.4.2. Technological Advancements
    • 2.3.4.3. Environmental Considerations
    • 2.3.4.4. Consumer Awareness & Acceptance
• 2.4. Estimation Methodology
• 2.5. Years Considered for the Study
• 2.6. Currency Conversion Rates

Chapter 3. Global Depression Drugs Market Dynamics

• 3.1. Market Drivers
  • 3.1.1. Advancements in Drug Development
  • 3.1.2. Rising Economic and Work-Related Stress
  • 3.1.3. Increasing Mental Health Awareness
• 3.2. Market Challenges
  • 3.2.1. Complexity in Supply Chain
  • 3.2.2. Generic Competition and Patent Cliffs
• 3.3. Market Opportunities
  • 3.3.1. Personalized Medicine and Pharmacogenomics
  • 3.3.2. Digital Therapeutics and Telemedicine
  • 3.3.3. Emerging Non-Drug Treatments

Chapter 4. Global Depression Drugs Market Industry Analysis

• 4.1. Porter's 5 Force Model
  • 4.1.1. Bargaining Power of Suppliers
  • 4.1.2. Bargaining Power of Buyers
  • 4.1.3. Threat of New Entrants
  • 4.1.4. Threat of Substitutes
  • 4.1.5. Competitive Rivalry
  • 4.1.6. Futuristic Approach to Porter's 5 Force Model
  • 4.1.7. Porter's 5 Force Impact Analysis
• 4.2. PESTEL Analysis
  • 4.2.1. Political
  • 4.2.2. Economical
  • 4.2.3. Social
  • 4.2.4. Technological
  • 4.2.5. Environmental
  • 4.2.6. Legal
• 4.3. Top investment opportunity
• 4.4. Top winning strategies
• 4.5. Disruptive Trends
• 4.6. Industry Expert Perspective
• 4.7. Analyst Recommendation & Conclusion

Chapter 5. Global Depression Drugs Market Size & Forecasts by Drug Class 2022-2032

• 5.1. Segment Dashboard
• 5.2. Global Depression Drugs Market: Drug Class Revenue Trend Analysis, 2022 & 2032 (USD Billion)
  • 5.2.1. Atypical Antipsychotics
  • 5.2.2. Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)
  • 5.2.3. Selective Serotonin Reuptake Inhibitors (SSRIs)
  • 5.2.4. Central Nervous System (CNS) Stimulants
  • 5.2.5. Tricyclic Antidepressants
  • 5.2.6. Monoamine Oxidase Inhibitors
  • 5.2.7. Others

Chapter 6. Global Depression Drugs Market Size & Forecasts by Disorder Type 2022-2032

• 6.1. Segment Dashboard
• 6.2. Global Depression Drugs Market: Disorder Type Revenue Trend Analysis, 2022 & 2032 (USD Billion)
  • 6.2.1. Major Depressive Disorder
  • 6.2.2. Obsessive-Compulsive Disorder
  • 6.2.3. Generalized Anxiety Disorder
  • 6.2.4. Panic Disorder
  • 6.2.5. Others

Chapter 7. Global Depression Drugs Market Size & Forecasts by Drug Type 2022-2032

• 7.1. Segment Dashboard
• 7.2. Global Depression Drugs Market: Drug Type Revenue Trend Analysis, 2022 & 2032 (USD Billion)
  • 7.2.1. Generic Drugs
  • 7.2.2. Branded Drugs

Chapter 8. Global Depression Drugs Market Size & Forecasts by Region 2022-2032

• 8.1. North America Depression Drugs Market
  • 8.1.1. U.S. Depression Drugs Market
    • 8.1.1.1. Drug Class breakdown size & forecasts, 2022-2032
    • 8.1.1.2. Disorder Type breakdown size & forecasts, 2022-2032
    • 8.1.1.3. Drug Type breakdown size & forecasts, 2022-2032
  • 8.1.2. Canada Depression Drugs Market
• 8.2. Europe Depression Drugs Market
  • 8.2.1. U.K. Depression Drugs Market
  • 8.2.2. Germany Depression Drugs Market
  • 8.2.3. France Depression Drugs Market
  • 8.2.4. Spain Depression Drugs Market
  • 8.2.5. Italy Depression Drugs Market
  • 8.2.6. Rest of Europe Depression Drugs Market
• 8.3. Asia-Pacific Depression Drugs Market
  • 8.3.1. China Depression Drugs Market
  • 8.3.2. India Depression Drugs Market
  • 8.3.3. Japan Depression Drugs Market
  • 8.3.4. Australia Depression Drugs Market
  • 8.3.5. South Korea Depression Drugs Market
  • 8.3.6. Rest of Asia Pacific Depression Drugs Market
• 8.4. Latin America Depression Drugs Market
  • 8.4.1. Brazil Depression Drugs Market
  • 8.4.2. Mexico Depression Drugs Market
  • 8.4.3. Rest of Latin America Depression Drugs Market
• 8.5. Middle East & Africa Depression Drugs Market
  • 8.5.1. Saudi Arabia Depression Drugs Market
  • 8.5.2. South Africa Depression Drugs Market
  • 8.5.3. Rest of Middle East & Africa Depression Drugs Market

Chapter 9. Competitive Intelligence

• 9.1. Key Company SWOT Analysis
• 9.2. Top Market Strategies
• 9.3. Company Profiles
  • 9.3.1. Otsuka Holdings Co., Ltd.
    • 9.3.1.1. Key Information
    • 9.3.1.2. Overview
    • 9.3.1.3. Financial (Subject to Data Availability)
    • 9.3.1.4. Product Summary
    • 9.3.1.5. Market Strategies
  • 9.3.2. Pfizer, Inc.
  • 9.3.3. Eli Lilly and Company
  • 9.3.4. AstraZeneca plc.
  • 9.3.5. Novartis AG
  • 9.3.6. Bristol-Myers Squibb Company
  • 9.3.7. GlaxoSmithKline plc.
  • 9.3.8. Takeda Pharmaceutical Co., Ltd.
  • 9.3.9. AbbVie, Inc.
  • 9.3.10. Johnson & Johnson

Chapter 10. Research Process

• 10.1. Research Process
  • 10.1.1. Data Mining
  • 10.1.2. Analysis
  • 10.1.3. Market Estimation
  • 10.1.4. Validation
  • 10.1.5. Publishing
• 10.2. Research Attributes